Platelet Inhibition with Cangrelor in Patients Undergoing PCI
Why the study?
Does intravenous cangrelor reduce the composite of death from any cause, myocardial infarction, or ischemia-driven revascularization compared to oral clopidogrel in patients with acute coronary syndromes undergoing PCI?
Population
n=8,877 patients with acute coronary syndromes undergoing percutaneous coronary intervention, international…
Comparison
Cangrelor administered intravenously 30 minutes… vs Oral loading dose of 600 mg of clopidogrel…
Design
RCT
Follow-up
48 hours
Authors
Discussion
Loading...
Member takes
Implication
Cangrelor confers no ischemic benefit over clopidogrel at 48 hours; confirms oral loading suffices as standard in ACS PCI.
Structured PICO
Does intravenous cangrelor reduce the composite of death from any cause, myocardial infarction, or ischemia-driven revascularization compared to oral clopidogrel in patients with acute coronary syndromes undergoing PCI?
P
Population
n=8,877 patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI), international trial.
I
Intervention
Cangrelor administered intravenously 30 minutes before PCI and continued for 2 hours after PCI
C
Comparator
Oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI
O
Outcome
Composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hourscomposite
Intravenous cangrelor was not superior to an oral loading dose of 600 mg of clopidogrel in reducing ischemic events at 48 hours in patients with acute coronary syndromes undergoing PCI.
Cite This Study
Harrington et al. (2009) studied this question.